In the context of endometriosis treatment, targeting partial suppression of the hypothalamus-pituitary-gonadal (HPG) axis through kisspeptin or neurokinin B antagonists could maintain therapeutic efficacy while avoiding drawbacks associated with GnRH. The gene discussed is GNRH1; the disease is endometriosis.